Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin
NCT ID: NCT04829903
Last Updated: 2022-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
116 participants
INTERVENTIONAL
2020-01-02
2021-11-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
NCT01508923
Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus
NCT01299012
Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects
NCT02408705
Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
NCT01234649
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
NCT03590626
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group DUL
Group taking Dulaglutide injections
Dulaglutide
Dulaglutide injections
Group LIR
Group taking Liraglutide injections
Liraglutide
Liraglutide injections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dulaglutide
Dulaglutide injections
Liraglutide
Liraglutide injections
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Obese
* Taking metformin
* Male or female
Exclusion Criteria
* Not taking metformin
* Taking other injectable diabetic medications
12 Years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corporacion Parc Tauli
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Zainab Khan
Chief Resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nadia Hussain, PhD
Role: PRINCIPAL_INVESTIGATOR
Al Ain University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Zainab Khan
Lahore, Punjab Province, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DULACAI37628
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.